Feb 19 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB ANNOUNCES OPDIVO® PLUS CHEMOTHERAPY AS THE FIRST AND ONLY NEOADJUVANT-ONLY IMMUNO-ONCOLOGY THERAPY TO DEMONSTRATE STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL OVERALL SURVIVAL IN RESECTABLE NON-SMALL CELL LUNG CANCER
BRISTOL-MYERS SQUIBB CO - STUDY SHOWS SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL WITH OPDIVO PLUS CHEMOTHERAPY
BRISTOL-MYERS SQUIBB CO - NO NEW SAFETY SIGNALS OBSERVED WITH OPDIVO PLUS CHEMOTHERAPY
Source text: ID:nBw3XKR9ga
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.